NCT06707922Csak meghívásos
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
A Multicenter, Prospective, Follow-up Study to Evaluate the Long-term Benefits of Peginterferon Alpha-2b Injection Combined With TDF in Patients With Chronic Hepatitis B
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2024. dec. 4. · Több mint 12 hónapja nem frissült - kérdezd meg a helyszínt, nyitott-e még
Rövid összefoglaló (regiszter, angolul)
Studies have shown that chronic hepatitis B patients with low levels of HBsAg after nucleos(t)ide analog therapy have a higher chance of functional cure with sequential or combined pegylated interferon therapy, with about 30-50% of patients achieving HBsAg clearance and discontinuing therapy. There are some clinical practices on the long-term benefits of discontinuing antiviral therapy, but there is a lack of evidence-based clinical studies, especially on the relapse rate, duration of relapse, and factors influencing relapse after achieving functional cure. Furthermore, there is no guideline or expert consensus on the follow-up management strategy for patients who haven't achieved functional cure but whose HBsAg levels have been substantially reduced by treatment and are at low levels. Therefore, this study is planned to enroll participants who have completed the TB1901IFN to evaluate the long-term benefit of Peginterferon in combination with tenofovir disoproxil fumarate（TDF） and relapse in patients who have achieved functional cure, for participant with low-level HBsAg at the end of treatment, peginterferon combined with tenofovir alafenamide fumarate （TAF）therapy will be administered to explore the efficacy and safety of starting treatment after a period of drug discontinuation. Participants will be divided into 3 cohorts based on functional achievement and/or HBsAg levels after completion of TB1901IFN
- Állapot (regiszter)
- Csak meghívásos
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 350 (tervezett)
- Első benyújtás
- 2024. nov. 24.
- Kezdés
- 2022. márc. 18.
- Elsődleges befejezés
- 2029. máj. 31.
- Fő szponzor
- Xiamen Amoytop Biotech Co., Ltd.
- Betegségek
- Hepatitis B (krónikus)
- NCT-szám
- NCT06707922
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Tervezett résztvevők: 350
- 2022. márc. 18. és az elsődleges befejezés (2029. máj. 31.) között
- 30 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Pregnant, breastfeeding women, or those who plan to conceive during the combined medication treatment period.
Más betegség
- Severe retinopathy or other severe ophthalmic diseases;
- Other conditions deemed by the investigator to be unsuitable for participation in the cohort 2.
- For cohort 3 only:
Laborértékek
- Evidence of acute severe liver injury: e.g. ALT > 10 times of the upper limit of normal (ULN), or a significant increase in ALT accompanied by a significant increase in bilirubin;
- Evidence of decompensated liver disease: serum total bilirubin > 2ULN, serum albumin < 35 g/L, prothrombin time extended by more than 3 seconds beyond ULN, prothrombin activity < 60%; or a history of decompensated liver cirrhosis;
- Kidney disease: acute or chronic nephritis, renal insufficiency, nephrotic syndrome, etc., or serum creatinine > 1ULN;
- Neutrophil count < 1.5×10\^9/L, platelet count < 90×10\^9/L;
Egyéb
- Suspected or confirmed HCC patients.
- For Cohort 2 only:
- Suspected or confirmed liver cirrhosis.
- Participants who plan to enter Cohort 2.
Kiket keres a vizsgálat
- Participants who completion of the TB1901IFN study ("completion" is defined as completion of more than 80% of trial medications (including peginterferon alfa and tenofovir disoproxil fumarate), or meeting criteria for early discontinuation and completion of consolidation therapy, as well as completion of discontinuation follow-up and 24-week post-discontinuation visit);
- Voluntary enrollment, understand and sign the informed consent form.
- For cohort 1 only; - Subjects who have achieved functional cure (defined as the disappearance of HBsAg at the completion of TB1901IFN, with or without the appearance of HBsAb);
- For cohort 2 only:
- At the completion of TB1901IFN, the S antigen level has decreased by ≥1 log compared to the baseline, with an S antigen level of less than 100 IU/ml, or the S antigen level has decreased by ≥1.5 log compared to the baseline, with an S antigen level of less than 1500 IU/ml;
- Willing to accept the treatment of peginterferon combined with TAF;
- For cohort 3 only:
- Participants who have not achieved functional cure upon completion of TB1901IFN (defined as HBsAg ≥ 0.05 IU/ml)；
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (30)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Peking University First Hospital | Beijing | Kína | Ismeretlen állapot |
| The Fifth Medical Center of PLA General Hospital | Beijing | Kína | Ismeretlen állapot |
| Beijing YouAn Hospital,Capital Medical University | Beijing | Kína | Ismeretlen állapot |
| The Second Xiangya Hospital of Central South University | Changsha | Kína | Ismeretlen állapot |
| Xiangya Hospital Central South University | Changsha | Kína | Ismeretlen állapot |
| Public Health Clinical Center of Chengdu | Chengdu | Kína | Ismeretlen állapot |
| Sichuan Provincial People's Hospital | Chengdu | Kína | Ismeretlen állapot |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou | Kína | Ismeretlen állapot |
| Mengchao Hepatobiliary Hosipital of Fujian Medical University | Fuzhou | Kína | Ismeretlen állapot |
| Guangzhou Eighth People's Hospital | Guangzhou | Kína | Ismeretlen állapot |
| The Third Affiliated Hospital,SUN YAT-SEN University | Guanzhou | Kína | Ismeretlen állapot |
| The Fourth Affiliated Hospital of Harbin Medical University | Harbin | Kína | Ismeretlen állapot |
| The First Affiliated Hospital of Anhui Medical University | Hefei | Kína | Ismeretlen állapot |
| Ruijin Hospital Shanghai Jiaotong University School of Medicine | Shanghai | Kína | Ismeretlen állapot |
| Huashan Hospital, Fudan University | Shanghai | Kína | Ismeretlen állapot |
| The Sixth People's Hospital of Shenyang | Shenyang | Kína | Ismeretlen állapot |
| The Third People's Hospital of Shenzhen | Shenzhen | Kína | Ismeretlen állapot |
| Peiking University Shenzhen Hospital | Shenzhen | Kína | Ismeretlen állapot |
| The First Hospital of Shanxi Medical University | Taiyuan | Kína | Ismeretlen állapot |
| First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | Tianjin | Kína | Ismeretlen állapot |
| Tianjin Third Central Hospital | Tianjin | Kína | Ismeretlen állapot |
| Traditional Chinese Medical hospital of Xinjiang Uygur Autonomous Region | Ürümqi | Kína | Ismeretlen állapot |
| The First Affiliated Hospital of Xinjiang Medical University | Ürümqi | Kína | Ismeretlen állapot |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Kína | Ismeretlen állapot |
| The First Affiliated hospital of Xiamen University | Xiamen | Kína | Ismeretlen állapot |
| Xiamen Hospital of Traditional Chinese Medicine | Xiamen | Kína | Ismeretlen állapot |
| Tangdu Hospital, Air Force Medical University | Xi'an | Kína | Ismeretlen állapot |
| The First Affiliated Hospital of Xi'an Jiaotong University | Xi’an | Kína | Ismeretlen állapot |
| Yanbian University Hospital (Yanbian Hospital) | Yanji | Kína | Ismeretlen állapot |
| Henan Provincial People's Hospital | Zhengzhou | Kína | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.